BenevolentAI S.A. (2XA.F)

0,6020 -0,0180 (-2,90%) Ab 03:29PM CEST. Markt geöffnet.

BenevolentAI S.A.

4-8 Maple Street
London W1T 5HD
United Kingdom
44 20 3781 9360
https://www.benevolent.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 248

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Joerg Moeller M.D., Ph.D.	CEO & Executive Director	N/A	N/A	N/A
Dr. Ivan Griffin Ph.D.	Co-Founder	350,69k	N/A	N/A
Ms. Catherine Isted A.C.M.A.	Chief Financial Officer	N/A	N/A	1975
Dr. James Malone	Chief Technology Officer	N/A	N/A	N/A
Dr. Anne Phelan	Chief Scientific Officer & Site Head for the Benevolent Cambridge Laboratories	354,38k	N/A	N/A
Ms. Fleur Wood	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Will Scrimshaw	General Counsel & Company Secretary	N/A	N/A	N/A
Ms. Anna Fullerton-Batten	Chief People Officer	N/A	N/A	N/A
Mr. Tom Holgate	Senior Vice President of Finance	N/A	N/A	N/A
Ms. Christina Busmalis	Chief Revenue Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Corporate Governance

BenevolentAI S.A.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.